Screener
Iovance Biotherapeutics, Inc. IOVA Business Segments — Operating Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| (in thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Expenses | ||||
| Research and development | $53,773 | $71,569 | $111,143 | $137,619 |
| General and administrative | 18,617 | 19,668 | 37,317 | 39,524 |
| Sales and marketing | 15,536 | 11,472 | 30,652 | 24,830 |
| Depreciation and amortization | 9,500 | 9,350 | 18,039 | 17,415 |
| Other segment items (b) | 5,607 | 10,670 | 13,859 | 26,114 |
| Total expenses | $103,033 | $122,729 | $211,010 | $245,502 |
| Net loss | $(47,315) | $(111,658) | $(126,360) | $(227,821) |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s business segments — operating expenses?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — operating expenses of $103.03M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — operating expenses changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — operating expenses decreased by 16.0% year-over-year, from $122.73M to $103.03M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s business segments — operating expenses?
- Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s business segments — operating expenses has grown at a 4.1% compound annual growth rate (CAGR), from $444.19M to $481.3M.
- What does business segments — operating expenses mean?
- Represents the total costs incurred by the business segment to support daily operations, including research, development, and administrative functions. Monitoring this metric helps investors assess the company's operational efficiency and the scale of investment required to sustain its clinical and commercial activities.
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude